We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+2.7%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
-$430M
Cap. Flow
-$140M
Cap. Flow %
-9.32%
Top 10 Hldgs %
47.39%
Holding
116
New
31
Increased
19
Reduced
31
Closed
29

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$31.2M
2
OGN icon
Organon & Co
OGN
+$23M
3
CYH icon
Community Health Systems
CYH
+$19.2M
4
RCM
R1 RCM Inc. Common Stock
RCM
+$18.6M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$17.3M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$71.3M
2
GSK icon
GSK
GSK
+$28.4M
3
TGTX icon
TG Therapeutics
TGTX
+$27.2M
4
ELV icon
Elevance Health
ELV
+$20.5M
5
CTLT
CATALENT, INC.
CTLT
+$17.2M

Sector Composition

Rank Sector Weight
1 Healthcare 65.27%
2 Miscellaneous 33.54%
3 Industrials 1.14%
4 Financials 0.05%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
51
Cullinan Oncology
CGEM
$1.4B
$4.22M 0.28%
+163,880
New +$5.04M
DXCM icon
52
DexCom
DXCM
$34.3B
$4.07M 0.27%
38,100
-36,864
-49% -$3.54M
ELV icon
53
Elevance Health
ELV
$85.5B
$3.87M 0.26%
10,132
-53,760
-84% -$20.5M
MRK icon
54
CALL
Merck
MRK
$366B
$3.79M 0.25%
+48,700
New +$3.62M
KDMN
55
DELISTED
Kadmon Holdings, Inc.
KDMN
$3.46M 0.23%
894,995
-478,124
-35% -$1.85M
EXEL icon
56
Exelixis
EXEL
$13.5B
$3.28M 0.22%
+180,000
New +$4.2M
AUTL
57
Autolus Therapeutics
AUTL
$623M
$3.14M 0.21%
+473,074
New +$2.94M
MRVI icon
58
Maravai LifeSciences
MRVI
$1.14B
$3.13M 0.21%
+75,000
New +$2.91M
XENT
59
DELISTED
Intersect ENT, Inc
XENT
$3M 0.2%
175,389
+100,000
+133% +$1.87M
IPSC icon
60
Century Therapeutics
IPSC
$367M
$2.96M 0.2%
+100,901
New +$2.56M
LQDA icon
61
Liquidia Corp
LQDA
$6.06B
$2.8M 0.19%
979,049
+479,039
+96% +$1.33M
TGTX icon
62
TG Therapeutics
TGTX
$8.26B
$2.71M 0.18%
69,760
-692,829
-91% -$27.2M
ISRG icon
63
Intuitive Surgical
ISRG
$132B
$2.38M 0.16%
7,749
– –
A icon
64
Agilent Technologies
A
$43.4B
$2.26M 0.15%
15,261
– –
HSTM icon
65
HealthStream
HSTM
$859M
$2.17M 0.14%
+77,812
New +$1.96M
OCUL icon
66
Ocular Therapeutix
OCUL
$2.28B
$2.13M 0.14%
+150,000
New +$2.28M
NVAX icon
67
CALL
Novavax
NVAX
$1.53B
$2.12M 0.14%
10,000
– –
HUMA icon
68
Humacyte
HUMA
$181M
$2.09M 0.14%
205,026
-34,000
-14% -$350K
ACAD icon
69
CALL
Acadia Pharmaceuticals
ACAD
$5.02B
$2.06M 0.14%
84,600
+59,600
+238% +$1.35M
TEVA icon
70
CALL
Teva Pharmaceuticals
TEVA
$42.5B
$1.91M 0.13%
+192,900
New +$2.04M
HCA icon
71
HCA Healthcare
HCA
$90.5B
$1.72M 0.11%
8,314
-77,095
-90% -$15.7M
MCRB icon
72
Seres Therapeutics
MCRB
$51.3M
$1.42M 0.09%
2,978
-7,786
-72% -$3.29M
GBT
73
PUT
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.4M 0.09%
+40,000
New +$1.56M
IQV icon
74
IQVIA
IQV
$43.1B
$1.38M 0.09%
5,712
-209
-4% -$48.3K
TLGT
75
DELISTED
Teligent, Inc
TLGT
$1.34M 0.09%
2,500,260
– –
1 2
3
4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2021 Portfolio in Review

As of Q2 2021, Eversept Partners held 116 positions worth $1.5B, down 22% from $1.93B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Eversept Partners withdrew a net $140M in Q2 2021, closing 29 positions and reducing 31 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $71.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 59% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, Eversept Partners opened a new position in Bristol-Myers Squibb worth $32M.

  • Eversept Partners's largest Q2 2021 buy was Bristol-Myers Squibb: 478,328 shares worth $32M.
  • Eversept Partners added most to Community Health Systems in Q2 2021, an estimated $19.2M increase.
  • Eversept Partners's biggest Q2 2021 reduction was GSK, cutting an estimated $28.4M.
  • Eversept Partners fully exited Alexion Pharmaceuticals in Q2 2021, selling an estimated $71.3M.
  • Eversept Partners's ten largest holdings make up 47% of its $1.5B portfolio in Q2 2021.
  • Eversept Partners opened 31 new positions and closed 29 in Q2 2021.
  • Eversept Partners's portfolio value fell 22% quarter-over-quarter to $1.5B.

Based on Eversept Partners's 13F filing for Q2 2021, filed 16 Aug 2021.